Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03432520 · ClinicalTrials.gov registry record
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
A clinical trial of Hemophilia A, sponsored by Spark Therapeutics.
- Active
- Registry status
- 29
- Enrollment target
- 12
- Study locations
NCT03432520 is a study of Hemophilia A that is active but no longer recruiting, run by Spark Therapeutics. The registered enrollment target is 29 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (68% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT03432520, a study of Hemophilia A, is active but no longer recruiting, sponsored by Spark Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 29 participants
- Enrollment target
- 12
- Study locations
Study Summary
This long-term follow-up study will continue to evaluate the long-term safety and efficacy of SPK-8011 and SPK-8016 in males with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any Spark-sponsored SPK-8011 or SPK-8016 study.
Conditions Studied
Interventions
- GENETIC SPK-8011
- GENETIC SPK-8016
Study Locations (12)
Pennsylvania
- Pennsylvania State University Milton S. Hershey Medical Center - Hershey
- The Children's Hospital of Philadelphia - Philadelphia
- Thomas Jefferson University - Philadelphia
- Hemophilia Center of Western Pennsylvania - Pittsburgh
Massachusetts
- Boston Children's Hospital - Boston
Mississippi
- Mississippi Center for Advanced Medicine - Madison
Missouri
- Truman Medical Centers - Kansas City
Oregon
- Oregon Health & Science University - Portland
Virginia
- Virginia Commonwealth University - Richmond
New South Wales
- Royal Prince Alfred Hospital Department of Cell & Molecular Therapies - Sydney
Victoria
- The Alfred Hospital & Monash Medical Centre - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2032-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03432520
The ClinicalTrials.gov registry entry for NCT03432520 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (68% lower). The listed sponsor is Spark Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 2 interventions - of which SPK-8011 is the first listed.
NCT03432520 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, Massachusetts, Mississippi.
Frequently Asked Questions
What is clinical trial NCT03432520 about?
NCT03432520 is a clinical study titled "Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A". This long-term follow-up study will continue to evaluate the long-term safety and efficacy of SPK-8011 and SPK-8016 in males with hemophilia A, who have received a single intravenous administration of SPK-8011 or SPK-8016 in any Spark-sponsored SPK-8011 or SPK-8016 study.
What is the current status of trial NCT03432520?
This trial is currently active not recruiting. The enrollment target is 29 participants. The study started on 2018-08-14. Estimated completion is 2032-12.
What conditions does trial NCT03432520 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT03432520?
The interventions under investigation include: SPK-8011 (GENETIC), SPK-8016 (GENETIC).
Who is sponsoring clinical trial NCT03432520?
This trial is sponsored by Spark Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03432520 being conducted?
This trial has 12 study locations across Massachusetts, Mississippi, Missouri, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.